A hallmark of unconventional immune effectors is their ability to recognize and eradicate tumor cells independently of classical MHC molecules, a critical advantage in malignancies where MHC class I downregulation enables tumors to elude CD8+ T-cell detection [55]. The gene discussed is CD8A; the disease is neoplasm.